Free shipping on all orders over $ 500

ABT-199 (Venetoclax)

Cat. No. M2017
ABT-199 (Venetoclax) Structure

GDC-0199, Venetoclax

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 65  USD65 In stock
2mg USD 27  USD27 In stock
5mg USD 50  USD50 In stock
10mg USD 65  USD65 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

ABT-199 (GDC-0199) is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. As a single agent, ABT-199 was as effective as ABT-737 in prolonging survival of immunocompetent tumor-bearing mice without causing thrombocytopenia. ABT-199 (GDC-0199) is an engineered version of ABT-263 (Navitoclax) but with much better selectivity.

Product Citations
Customer Product Validations & Biological Datas
Source Cell Death & Disease (2018). Figure 2. ABT199 (Abmole Bioscience)
Method Cell viability analysis
Cell Lines MDA-MB-231, MDA-MB-157, and MDA-MB-468 cells
Concentrations 1 μM
Incubation Time 24 h
Results But treatment with Temsirolimus in combination with ABT263 or ABT199 only induced modest cell viability inhibition.
Source Oncotarget (2015). Figure 5. ABT 199 (Abmole BioScience)
Method Cell viability assay and Western blot
Cell Lines SNU668 and SNU638 cells
Concentrations 1 µM
Incubation Time 24 h
Results Combination 5-aza-dC and LPS treatment enhances binding activity of Sp1 and H3K4me3 in gastric cancer cells via activation of TLR4 signaling.
Protocol (for reference only)
Cell Experiment
Cell lines CLL cells and platelets
Preparation method Apoptosis analysis Peripheral blood mononuclear cells were purified using Histopaque and cultured in RPMI 1640 medium supplemented with 10% fetal calf serum and 2 mmol/l L-glutamine at2*106 cells/ml. Cells were exposed to different concentrations of ABT-737, ABT-263, or ABT-199 for 4 h before analysis of apoptosis by externalisation of phosphatidylserine (PS) and binding of AnnexinV/fluorescein isothiocyanate (FITC). Platelets isolated from healthy volunteers were cultured in Hepes-buffered saline and exposed to different concentrations of ABT-737, ABT-263, or ABT-199 for 4 h before analysis of apoptosis in the CD41-positive population by externalisation of PS and binding of AnnexinV/FITC.
Concentrations 0~3µM
Incubation time 4 h
Animal Experiment
Animal models C57BL/6 mice were injected (i.v.) with 3x106 T1 lymphoma cells
Formulation formulated in 60% phosal 50PG (standardized phosphatidylcholine concentrate with at least 50% PC and propylene glycol
Dosages 100 mg/kg
Administration oral gavage
Chemical Information
Molecular Weight 868.44
Formula C45H50ClN7O7S
CAS Number 1257044-40-8
Solubility (25°C) DMSO 80 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Vandenberg CJ, et al. Blood. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.

[2] Souers AJ, et al. Nat Med. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Related Bcl-2 Products
Mcl-1 inhibitor 6

Mcl-1 inhibitor 6 is an orally active, selective myeloid cell leukemia 1 (Mcl-1) protein inhibitor with a Kd of 0.23 nM and a Ki of 0.02 μM. Mcl-1 inhibitor 6 possesses superior selectivity over other Bcl-2 family members (Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w, Kd>10 μM).


UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR).


Lisaftoclax (APG-2575) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively.


VU661013 is a novel, potent, selective MCL1 inhibitor with Ki of 97 ± 30 pM to human MCL-1 in a TR-FRET assay. VU661013 destabilizes BIM/MCL1 association, leads to apoptosis in AML, and is active in venetoclax-resistant cells and xenografts.


CCT369260 is an orally active, B-cell lymphoma 6 (BCL6) inhibitor with antitumor activity and an IC50 value of 520 nM.

Abmole Inhibitor Catalog

Keywords: ABT-199 (Venetoclax), GDC-0199, Venetoclax supplier, Bcl-2, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.